AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

GRI Bio, Inc.

$1.9 -$5.94 (-75.77%)
NASDAQ · 11 Sep 2026 20:00 UTC
Previous Close
$1.94
Day Range
$1.85$2.05
Year Range
$1.36$64.12
Market Cap
170.68K
AVG Volume
251.26K
Trailing/Forward PE
-0.04/-
PEG ratio
0
Dividend Yield
-
Next Earnings Date
2026-11-13
Primary Exchange
NASDAQUS
Revenue (USD)
00.250.50.75124 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
GRI Revenue (USD) by quarter
PeriodRevenue (USD)
26 Q20
26 Q10
25 Q40
25 Q30
25 Q20
25 Q10
24 Q40
24 Q30
24 Q20
24 Q10
Net Income (USD)
-4M-3M-2M-1M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
GRI Net Income (USD) by quarter
PeriodNet Income (USD)
26 Q2-1.64M
26 Q1-2M
25 Q4-2.66M
25 Q3-3.36M
25 Q2-2.89M
25 Q1-3.05M
24 Q4-1.95M
24 Q3-2.12M
24 Q2-2.25M
24 Q1-1.89M
Operating Income (USD)
-4M-3M-2M-1M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
GRI Operating Income (USD) by quarter
PeriodOperating Income (USD)
26 Q2-1.65M
26 Q1-2M
25 Q4-2.66M
25 Q3-3.37M
25 Q2-2.9M
25 Q1-3.05M
24 Q4-1.95M
24 Q3-2.13M
24 Q2-2.26M
24 Q1-1.9M
EBITDA (USD)
-4M-3M-2M-1M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
GRI EBITDA (USD) by quarter
PeriodEBITDA (USD)
26 Q2-1.65M
26 Q1-2M
25 Q4-2.66M
25 Q3-3.36M
25 Q2-2.9M
25 Q1-3.05M
24 Q4-1.95M
24 Q3-2.12M
24 Q2-2.25M
24 Q1-1.89M
Cash Flows (USD)
-4M-3M-2M-1M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
GRI Cash Flows (USD) by quarter
PeriodCash Flows (USD)
26 Q2-1.45M
26 Q1-3.69M
25 Q4-2.97M
25 Q3-2.31M
25 Q2-3.17M
25 Q1-2.13M
24 Q4-2M
24 Q3-2.27M
24 Q2-2.14M
24 Q1-2.2M
EPS (USD)
-3000-2000-1000024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
GRI EPS (USD) by quarter
PeriodEPS (USD)
26 Q2-0.91
26 Q1-1.61
25 Q4-5.34
25 Q3-35.84
25 Q2-36.68
25 Q1-162.4
24 Q4-220.08
24 Q3-319.76
24 Q2-1731.8
24 Q1-2829.12
Expenses (USD)
01M2M3M4MR&DSG&ACapex24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
GRI Expenses (USD) by quarter
PeriodExpenses (USD)
26 Q21.65M
26 Q12M
25 Q42.67M
25 Q33.37M
25 Q22.9M
25 Q13.45M
24 Q41.95M
24 Q32.13M
24 Q22.26M
24 Q11.89M
Cash & Debt (USD)
05M10M15MCashLong Term DebtShort Term Debt24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
GRI Cash & Debt (USD) by quarter
PeriodCash & Debt (USD)
26 Q210.95M
26 Q111.05M
25 Q48.23M
25 Q34.05M
25 Q25.12M
25 Q13.28M
24 Q45.03M
24 Q34.75M
24 Q26.35M
24 Q14.09M
Debt ratios
-0.500.511.522 Q222 Q322 Q423 Q424 Q124 Q224 Q325 Q426 Q126 Q2
GRI Debt ratios by quarter
PeriodDebt ratios
26 Q21.13
26 Q11.01
25 Q40.68
24 Q30.56
24 Q20.75
24 Q10.33
23 Q40.16
22 Q4-0.13
22 Q30.22
22 Q20.97
Margins
-1500%-1000%-500%0%20 Q1
GRI Margins by quarter
PeriodMargins
20 Q1-1161%
Return on Capital
-800%-600%-400%-200%0%23 Q424 Q124 Q224 Q325 Q125 Q225 Q325 Q426 Q126 Q2
GRI Return on Capital by quarter
PeriodReturn on Capital
26 Q2-15.98%
26 Q1-18.95%
25 Q4-44.26%
25 Q3-168.54%
25 Q2-87.06%
25 Q1-252.78%
24 Q3-58.01%
24 Q2-47.68%
24 Q1-67.44%
23 Q4-773.75%
Shares Outstanding
0500K1M1.5M2M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
GRI Shares Outstanding by quarter
PeriodShares Outstanding
26 Q21.8M
26 Q11.24M
25 Q4497.7K
25 Q393.62K
25 Q278.75K
25 Q118.77K
24 Q46.55K
24 Q36.64K
24 Q216.35K
24 Q111.34K
Dividends (USD)
00.511.5Dec 08
GRI Dividends (USD) by quarter
PeriodDividends (USD)
Dec 080.49
Book Value Per Share (USD)
020040060023 Q424 Q124 Q224 Q325 Q125 Q225 Q325 Q426 Q126 Q2
GRI Book Value Per Share (USD) by quarter
PeriodBook Value Per Share (USD)
26 Q25.7
26 Q18.5
25 Q412.07
25 Q321.29
25 Q242.18
25 Q164.21
24 Q3551.2
24 Q2288.68
24 Q1246.76
23 Q4146
Total Assets (USD)
05M10M15M24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
GRI Total Assets (USD) by quarter
PeriodTotal Assets (USD)
26 Q211.38M
26 Q111.34M
25 Q48.67M
25 Q34.78M
25 Q25.67M
25 Q14.04M
24 Q45.74M
24 Q35.46M
24 Q27.03M
24 Q14.59M
Free Cash Flow Yield
-6000%-4000%-2000%0%med -349.08%Jan 23May 23Oct 24Jan 25Feb 26May 26Sep 26
GRI Free Cash Flow Yield by quarter
PeriodFree Cash Flow Yield
Sep 26-303.78%
Sep 26-200.41%
Aug 26-300.62%
Aug 26-349.81%
Aug 26-345.62%
Aug 26-665.36%
Jul 26-1541.16%
Jul 26-1466.76%
Jul 26-1417.87%
Jul 26-1222.3%
Jul 26-1137.33%
Jun 26-1168.57%
Jun 26-1131.28%
Jun 26-945.24%
Jun 26-1063.4%
May 26-1032.43%
May 26-1032.43%
May 26-1047.68%
May 26-945.24%
May 26-975.6%
Apr 26-916.72%
Apr 26-834.04%
Apr 26-868.08%
Apr 26-893.61%
Mar 26-932.81%
Mar 26-901.19%
Mar 26-4041.08%
Mar 26-3993.91%
Feb 26-4025.24%
Feb 26-4122.23%
Feb 26-4443.44%
Feb 26-4294.71%
Jan 26-3148.57%
Jan 26-1819.92%
Jan 26-1647.57%
Jan 26-1629.26%
Jan 26-1309.23%
Dec 25-1327.86%
Dec 25-1078.19%
Mar 25-1092.97%
Mar 25-998%
Feb 25-826.63%
Feb 25-927.32%
Feb 25-700.2%
Feb 25-804.29%
Jan 25-609.58%
Jan 25-626.5%
Jan 25-534.44%
Jan 25-505.16%
Jan 25-424.57%
Dec 24-495.6%
Dec 24-520.42%
Dec 24-180.16%
Dec 24-182.44%
Nov 24-210.86%
Nov 24-209.24%
Nov 24-186.61%
Nov 24-164.66%
Nov 24-131.03%
Oct 24-201%
Oct 24-248.5%
Oct 24-357.17%
Oct 24-402.33%
Sep 24-323.25%
Sep 24-327.13%
Sep 24-340.6%
Sep 24-333.95%
Aug 24-337.05%
Aug 24-336.27%
Aug 24-348.35%
Aug 24-329.04%
Aug 24-317.55%
May 23-0.25%
May 23-0.23%
May 23-0.23%
May 23-0.2%
Apr 23-0.2%
Apr 23-0.12%
Apr 23-0.13%
Apr 23-0.12%
Mar 23-0.13%
Mar 23-0.12%
Mar 23-0.11%
Mar 23-0.11%
Mar 23-0.12%
Feb 23-0.15%
Feb 23-0.11%
Feb 23-0.19%
Feb 23-0.31%
Jan 23-0.32%
Jan 23-0.3%
Jan 23-0.33%
Jan 23-0.32%
Dec 22-0.31%
Dec 22-0.31%
Dec 22-0.3%
Dec 22-0.39%
Dec 22-0.37%
Nov 22-0.81%
Nov 22-0.74%
Price to Sales
400006000080000100000med 53318.38Feb 21Mar 21Mar 21Apr 21May 21May 21
GRI Price to Sales by quarter
PeriodPrice to Sales
May 2146313.47
May 2144345.14
May 2142376.82
May 2147239.74
Apr 2149555.41
Apr 2151986.87
Apr 2152681.57
Apr 2153955.19
Apr 2156502.43
Mar 2151060.6
Mar 2158123.4
Mar 2164375.72
Mar 2157903.41
Feb 2170743.82
Feb 2181511.7
Feb 2190658.61
Price to Book
051015med 0.61Jul 24Nov 24Feb 25Oct 25Feb 26May 26Sep 26
GRI Price to Book by quarter
PeriodPrice to Book
Sep 260.33
Sep 260.51
Aug 260.34
Aug 260.29
Aug 260.29
Aug 260.17
Jul 260.11
Jul 260.12
Jul 260.12
Jul 260.14
Jul 260.15
Jun 260.15
Jun 260.16
Jun 260.19
Jun 260.17
May 260.17
May 260.17
May 260.17
May 260.19
May 260.18
Apr 260.19
Apr 260.21
Apr 260.2
Apr 260.2
Mar 260.19
Mar 260.2
Mar 260.12
Mar 260.12
Feb 260.12
Feb 260.12
Feb 260.11
Feb 260.11
Jan 260.15
Jan 260.26
Jan 260.29
Jan 260.3
Jan 260.37
Dec 250.36
Dec 250.45
Dec 250.35
Dec 251.37
Nov 251.33
Nov 251.36
Nov 251.12
Nov 251.12
Oct 251.13
Oct 251.36
Oct 251.29
Oct 251.23
Oct 251.27
Sep 251.29
Sep 251.2
Sep 251.2
Sep 250.72
Aug 250.61
Aug 250.61
Aug 250.61
Mar 250.3
Mar 250.33
Feb 250.4
Feb 250.36
Feb 250.47
Feb 250.41
Jan 250.55
Jan 250.53
Jan 250.62
Jan 250.66
Jan 250.78
Dec 240.67
Dec 240.64
Dec 241.32
Dec 241.3
Nov 241.13
Nov 241.14
Nov 241.27
Nov 241.44
Nov 241.81
Oct 241.18
Oct 240.96
Oct 240.67
Oct 240.59
Sep 240.74
Sep 240.73
Sep 240.97
Sep 240.99
Aug 240.98
Aug 240.98
Aug 240.95
Aug 241
Aug 241.04
Jul 244.11
Jul 245.44
Jul 245.67
Jul 245.12
Jun 246.26
Jun 248.67
Jun 249.66
Jun 2411.8
May 2412.8
May 2413.48
GRI Bio, Inc.
GRI
Stockpicker

Video analysis: GRI

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: GRI

GRI Bio Presents New Phase 2a Data at ERS 2026 Defining GRI-0621's Mechanism of Action in IPF Across Nine Mechanistic Pillars

globenewswire.com · 8 Sep 2026

GRI Bio Presents New Phase 2a Data at ERS 2026 Defining GRI-0621's Mechanism of Action in IPF Across Nine Mechanistic Pillars

New whole blood RNA sequencing data identified coordinated, consistent change in genes governing immune re-balancing, myofibroblast inhibition, fibrolysis, basement membrane repair, re-epithelialization, antitussive effect and GI protection

GRI Bio Featured in "Why Now" On-Demand Video Webcast

globenewswire.com · 27 Aug 2026

GRI Bio Featured in "Why Now" On-Demand Video Webcast

Video webcast now available  here

GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026

globenewswire.com · 24 Aug 2026

GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026

LA JOLLA, CA, Aug. 24, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company developing innovative therapies for inflammatory, fibrotic and autoimmune diseases, today announced that three abstracts and an oral presentation highlighting data from the Phase 2a GRI-0621-IPF-02 study have been selected for presentation at the 2026 European Respiratory Society (ERS) Congress, being held September 5-9, 2026 in Barcelona, Spain.

Bitcoin surges above $70K as Trump backs Clarity Act, Treasury ramps up buybacks

nypost.com · 20 Aug 2026

Bitcoin surges above $70K as Trump backs Clarity Act, Treasury ramps up buybacks

Bitcoin jumped 4.6% to $72,475.25 – a roughly 12% gain over the past two days after the digital asset was trading near $63,000 earlier this week.

Ingevity Releases 2025 Sustainability Report, Highlights Performance and Impact

gurufocus.com · 5 Aug 2026

Ingevity Releases 2025 Sustainability Report, Highlights Performance and Impact

Ingevity Corporation (NYSE: NGVT) today announced it has published its [url="]2025 Sustainability Report[/url] featuring the company's advanced materials and tec

Ingram Micro Releases 2025 Sustainable Impact Report

gurufocus.com · 3 Aug 2026

Ingram Micro Releases 2025 Sustainable Impact Report

Ingram Micro today released its 2025 Sustainable Impact Report, detailing the company's progress made through 2025 to reduce carbon emissions, advance zero-wast

Williams Improves on Key Sustainability Metrics Amid Rising Energy Demand

gurufocus.com · 30 Jul 2026

Williams Improves on Key Sustainability Metrics Amid Rising Energy Demand

Williams (NYSE: WMB) today released its 2025 Sustainability Report, highlighting its environmental, safety and operational performance amid rapidly growing dema

Banner Bank Releases New Corporate Responsibility Report

gurufocus.com · 14 Jul 2026

Banner Bank Releases New Corporate Responsibility Report

Today, Banner Bank released its 2025 Corporate Responsibility Report. The report identifies ongoing practices and recent accomplishments that contribute to crea

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.